PPARG and hepatocellular carcinoma: Recent studies have demonstrated that PPARγ agonists may induce growth inhibition in hepatocellular carcinoma (HCC) cells in a dose- and time-dependent manner (Koga et al, 2001; Rumi et al, 2001; Yoshizawa et al, 2002).